Before making a move on any particular stock, readers often pay close attention to support and resistance markers. The last reported price for shares of Regeneron Pharmaceuticals, Inc. (REGN) was $391.80. Currently, the 1st Resistance Point for this stock is $399.12, with a 2nd Resistance Point sitting at $406.44. Meanwhile, this company’s stock has a 1st Support Level at $387.95 and a 2nd Support Level at $384.11. Regeneron Pharmaceuticals, Inc. (REGN) stock has lost -$22.67, or -5.47%, in the past five days. In the last full month, these shares have lost -$30.72, or -7.27%. In the past three months, this stock’s price has risen by $47.20, or 13.70%. This year-to-date, Regeneron Pharmaceuticals, Inc. (REGN) shares have gained $18.30, or 4.90%.
Analyzing price projection indicators is a helpful way to determine whether a potential stock buy is a wise choice for profits in the short term, medium term, and long term. For Regeneron Pharmaceuticals, Inc. (REGN) stock, 60% of short-term indicators suggest that these shares are a “ Sell .” Meanwhile, 50% of medium-term indicators point to this stock being a “ Sell .” Looking further ahead, 67% of long-term indicators suggest that this stock is a “ Buy .”
With 109,276 K shares outstanding, this company currently has a market capitalization of $42,814,336K. Regeneron Pharmaceuticals, Inc. (REGN) generates $6,711 M in annual sales, amounting to annual net income of $2,444 M. This stock has generated a 1-Year Total Return of 19.56%, a 3-Year Total Return of 5.66%, and a 5-year Total Return of 30.56%. This stock’s 5-Year Dividend Growth is 0.00. Its Annual Dividend Yield is 0.00%, and its Annual Dividend Rate is 0.00.
In the most recently-reported fiscal quarter, which ended in Dec-18, Regeneron Pharmaceuticals, Inc. (REGN) reported earnings of $6.84 per share. Wall Street analysts, on average, were expecting the company to report earnings of $5.60 per share, representing a 1.24 difference and 22.18% surprise. In the previous quarter ending in Sep-18, the reported earnings of $5.87 represented a 0.74 difference from the consensus estimate calling for $5.13 per share, which was a 14.36% surprise.
For the current fiscal quarter, which is set to end in 03/2019, the average earnings estimate is $5.24 per share. This estimate came from a total of 1 Wall Street Analysts. Of those market experts, the high estimate was $5.24 and the low estimate was $5.24. In the year-ago quarter, Regeneron Pharmaceuticals, Inc. (REGN) generated per-share earnings of $3.98. If the analysts are correct about the current quarter’s earnings, the growth will be +31.66% .
Turning our focus now to insider trading activity, there have been 12 purchases (4,998 shares in total) and 3 sale (133,056 shares in total) in the last 3 months. In the last 6 months, there have been 26 insider buys amounting to 719,823 shares and 33 insider sales amounting to 647,262 shares. In the past full year, 41 insider purchases were made (involving 1,464,085 shares) and 82 insider sell-offs equivalent to 1,659,213 shares.
Moving onto liquidity, Regeneron Pharmaceuticals, Inc. (REGN) has a Current Ratio of 4.47, a Quick Ratio of 3.67 and a Cash Ratio of 1.95. Looking at this company’s capital structure, its Total Debt to Total Equity is 8.09, its Total Debt to Total Capital is 7.48, and its Total Debt to Total Assets is now 6.04. Looking even further ahead into the future, its Long-Term Debt to Equity is 8.09 and its Long-Term Debt to Total Capital is 7.48.